Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?
Why the RASolute 309 trial matters for Revolution Medicines
Revolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib as a first-line option for metastatic RAS G12D pancreatic cancer.
The study compares this combination against standard chemotherapy gemcitabine and nab paclitaxel, with progression free survival and overall survival as dual primary endpoints that investors will watch closely.
Revolution Medicines sits at US$189.76 after a 1-day share price return of 0.87%. However, the 7-day and 30-day share price returns are down 8.17% and 8.63%, hinting at cooling short-term momentum after a strong year-to-date share price gain of 140.14% and a 1-year total shareholder return of 293.37% that builds on very large 3-year and 5-year total shareholder return figures.
Scan beyond Revolution Medicines and identify other high conviction oncology players using the curated 20 high quality undiscovered gems that is aligned with similar high-impact clinical pipelines.
Revolution Medicines has rallied hard yet now trades well below the average analyst estimate, so where might a reasonable fair value range actually sit after this latest move?
Most Popular Narrative: 26% Undervalued
On the most followed view, Revolution Medicines screens as undervalued, with a fair value of $257.47 against the last close at $189.76. This sets a high bar for what the RASolute 309 and broader RAS program need to deliver.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio. This could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years. These could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.
See why 15 investors see Revolution Medicines as 26% undervalued.
Result: Fair Value of $257.47 (UNDERVALUED)
Still, the Revolution Medicines story could change quickly if high cost R&D fails to translate into approvals, or if RAS focused trials deliver weaker than expected data.
Find out about the key risks to this Revolution Medicines narrative.
Another View: Revolution Medicines on traditional multiples
Analyst models and SWS fair value work suggest Revolution Medicines looks cheap against future cash flow, yet the current P/B of 15.6x is far above the US Biotechs average of 2.1x and above peer levels of 12.5x. If the market leans back toward those benchmarks, how comfortable are you with that valuation swing?
For a closer look at what the current ratio says about valuation risk versus upside, take a moment with See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages in the Revolution Medicines story today. For a clear take, move quickly, review the data, and weigh both sides by examining the 3 key rewards and 2 important warning signs.
Looking for more Revolution Medicines style investment ideas?
Revolution Medicines offers one angle on high impact oncology, but building a resilient portfolio means lining up a few different sources of potential return across sectors.
Use the Simply Wall St Screener to uncover other stocks with strong fundamentals, distinctive return profiles and balance sheets that can handle tougher conditions without falling apart.
- Target mispriced quality and let the numbers guide you toward potential value opportunities with the 28 high quality undervalued stocks.
- Prioritise staying power and protect your downside by focusing on companies highlighted in the 31 resilient stocks with low risk scores.
- Strengthen your core holdings by concentrating on financially robust businesses sourced from the list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com